Findings

What do systematic reviews say?

167 questions · 170 findings · 8 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 21 · 12.4%GRADE not reported 0 · 0%Very low 7 · 4.1%Low 34 · 20%Moderate 84 · 49.4%High 24 · 14.1%

Factor Xa inhibitors vs Anticoagulants

All causes of mortality at 30 days · Anticoagulants in ACS

Factor Xa inhibitors showed no clear difference in all causes of mortality at 30 days compared with anticoagulants (high certainty).

1 finding from 1 review

Factor Xa inhibitors for acute coronary syndromes 2011 · Cochrane Headline outcomes only
RR 0.9 [0.8, 1.01]
4 studies · 27976 participants
High

Factor Xa inhibitors vs Anticoagulants

All causes of mortality at 30 days ‐ UFH · Anticoagulants in ACS

Factor Xa inhibitors showed no clear difference in all causes of mortality at 30 days ‐ UFH compared with anticoagulants (high certainty).

1 finding from 1 review

Factor Xa inhibitors for acute coronary syndromes 2011 · Cochrane Headline outcomes only
RR 0.98 [0.82, 1.18]
2 studies · 6760 participants
High

Factor Xa inhibitors vs Anticoagulants

All causes of mortality at 30 days ‐ Enoxaparin · Anticoagulants in ACS

Factor Xa inhibitors leads to lower all causes of mortality at 30 days ‐ Enoxaparin compared with anticoagulants (high certainty).

1 finding from 1 review

Factor Xa inhibitors for acute coronary syndromes 2011 · Cochrane Headline outcomes only
RR 0.85 [0.73, 0.98]
2 studies · 21216 participants
High

Factor Xa inhibitors vs Anticoagulants

Major bleeding · Anticoagulants in ACS

Factor Xa inhibitors showed no clear difference in major bleeding at 30 days compared with anticoagulants (high certainty).

2 findings from 1 review

Factor Xa inhibitors for acute coronary syndromes 2011 · Cochrane Headline outcomes only
RR 1.01 [0.98, 1.04]
2 studies · 20404 participants
High
Factor Xa inhibitors for acute coronary syndromes 2011 · Cochrane Headline outcomes only
RR 0.98 [0.92, 1.04]
1 study · 326 participants
High

Factor Xa inhibitors vs Anticoagulants

Major bleeding at 30 days ‐ Enoxaparin · Anticoagulants in ACS

Factor Xa inhibitors leads to higher major bleeding at 30 days ‐ Enoxaparin compared with anticoagulants (high certainty).

1 finding from 1 review

Factor Xa inhibitors for acute coronary syndromes 2011 · Cochrane Headline outcomes only
RR 1.02 [1.01, 1.02]
1 study · 20078 participants
High

Factor Xa inhibitors vs Anticoagulants

Minor bleeding · Anticoagulants in ACS

Factor Xa inhibitors showed no clear difference in minor bleeding at 30 days compared with anticoagulants (high certainty).

3 findings from 1 review

Factor Xa inhibitors for acute coronary syndromes 2011 · Cochrane Headline outcomes only
RR 0.7 [0.14, 3.39]
2 studies · 20404 participants
High
Factor Xa inhibitors for acute coronary syndromes 2011 · Cochrane Headline outcomes only
RR 1.76 [0.52, 5.94]
1 study · 326 participants
Moderate
Factor Xa inhibitors for acute coronary syndromes 2011 · Cochrane Headline outcomes only
RR 0.34 [0.28, 0.43]
1 study · 20078 participants
High

Oral factor Xa inhibitors vs conventional anticoagulation

Non‐fatal PE (3 to 12 months) · participants with diagnosed DVT

Oral factor Xa inhibitors showed no clear difference in non‐fatal PE (3 to 12 months) compared with conventional anticoagulation (moderate certainty).

1 finding from 1 review

Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of… 2023 · Cochrane Headline outcomes only
OR 0.93 [0.68, 1.27]
7 studies · 15166 participants
Moderate

Oral factor Xa inhibitors vs conventional anticoagulation

All‐cause mortality (3 to 6 months) · participants with diagnosed DVT

Oral factor Xa inhibitors showed no clear difference in all‐cause mortality (3 to 6 months) compared with conventional anticoagulation (moderate certainty).

1 finding from 1 review

Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of… 2023 · Cochrane Headline outcomes only
OR 0.87 [0.67, 1.14]
9 studies · 10770 participants
Moderate

Oral factor Xa inhibitors vs conventional anticoagulation

Major bleeding · participants with diagnosed DVT

Oral factor Xa inhibitors leads to lower major bleeding (3 to 12 months) compared with conventional anticoagulation (high certainty).

1 finding from 1 review

Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of… 2023 · Cochrane Headline outcomes only
OR 0.63 [0.45, 0.89]
17 studies · 18066 participants
High

Oral factor Xa inhibitors vs conventional anticoagulation

Recurrent VTE · participants with diagnosed DVT

Oral factor Xa inhibitors showed no clear difference in recurrent VTE (3 to 12 months) compared with conventional anticoagulation (moderate certainty).

1 finding from 1 review

Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of… 2023 · Cochrane Headline outcomes only
OR 0.85 [0.71, 1.01]
13 studies · 17505 participants
Moderate

Oral factor Xa inhibitors vs conventional anticoagulation

Recurrent DVT (3 to 12 months) · participants with diagnosed DVT

Oral factor Xa inhibitors showed no clear difference in recurrent DVT (3 to 12 months) compared with conventional anticoagulation (moderate certainty).

1 finding from 1 review

Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of… 2023 · Cochrane Headline outcomes only
OR 0.7 [0.49, 1.01]
9 studies · 16439 participants
Moderate

Oral factor Xa inhibitors vs conventional anticoagulation

Fatal PE (3 to 12 months) · participants with diagnosed DVT

Oral factor Xa inhibitors showed no clear difference in fatal PE (3 to 12 months) compared with conventional anticoagulation (moderate certainty).

1 finding from 1 review

Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of… 2023 · Cochrane Headline outcomes only
OR 1.18 [0.69, 2.02]
6 studies · 15082 participants
Moderate

Oral factor Xa inhibitors vs conventional anticoagulation

All‐cause mortality · patients with a pulmonary embolism, confirmed by standard imaging techniques

Oral factor Xa inhibitors showed no clear difference in all‐cause mortality compared with conventional anticoagulation (moderate certainty).

1 finding from 1 review

Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of… 2023 · Cochrane Headline outcomes only
OR 1.16 [0.79, 1.7]
1 study · 4817 participants
Moderate

Oral factor Xa inhibitors vs conventional anticoagulation

Major bleedinge · patients with a pulmonary embolism, confirmed by standard imaging techniques

Oral factor Xa inhibitors showed no clear difference in major bleedinge compared with conventional anticoagulation (low certainty).

1 finding from 1 review

Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of… 2023 · Cochrane Headline outcomes only
OR 0.71 [0.36, 1.41]
8 studies · 11447 participants
Low

Oral factor Xa inhibitors vs conventional anticoagulation

Health‐related quality of life · patients with a pulmonary embolism, confirmed by standard imaging techniques

The review found no eligible studies for this question.

1 finding from 1 review

Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral factor Xa inhibitors vs conventional anticoagulation

Recurrent PE · patients with a pulmonary embolism, confirmed by standard imaging techniques

Oral factor Xa inhibitors showed no clear difference in recurrent PEa compared with conventional anticoagulation (moderate certainty).

1 finding from 1 review

Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of… 2023 · Cochrane Headline outcomes only
OR 0.92 [0.66, 1.29]
3 studies · 8186 participants
Moderate

Oral factor Xa inhibitors vs conventional anticoagulation

Recurrent VTEc · patients with a pulmonary embolism, confirmed by standard imaging techniques

Oral factor Xa inhibitors showed no clear difference in recurrent VTEc compared with conventional anticoagulation (moderate certainty).

1 finding from 1 review

Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of… 2023 · Cochrane Headline outcomes only
OR 0.83 [0.66, 1.03]
8 studies · 11416 participants
Moderate

Oral factor Xa inhibitors vs conventional anticoagulation

DVTd · patients with a pulmonary embolism, confirmed by standard imaging techniques

Oral factor Xa inhibitors showed no clear difference in DVTd compared with conventional anticoagulation (moderate certainty).

1 finding from 1 review

Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of… 2023 · Cochrane Headline outcomes only
OR 0.77 [0.48, 1.25]
2 studies · 8151 participants
Moderate

Oral direct thrombin inhibitors (DTIs) vs conventional anticoagulation

Recurrent PE · patients with a pulmonary embolism, confirmed by standard imaging techniques

Oral direct thrombin inhibitors (DTIs) showed no clear difference in recurrent PEa compared with conventional anticoagulation (moderate certainty).

1 finding from 1 review

Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of… 2023 · Cochrane Headline outcomes only
OR 1.02 [0.5, 2.04]
1 study · 1602 participants
Moderate

Oral direct thrombin inhibitors (DTIs) vs conventional anticoagulation

Recurrent VTEc · patients with a pulmonary embolism, confirmed by standard imaging techniques

Oral direct thrombin inhibitors (DTIs) showed no clear difference in recurrent VTEc compared with conventional anticoagulation (moderate certainty).

1 finding from 1 review

Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of… 2023 · Cochrane Headline outcomes only
OR 0.93 [0.52, 1.66]
1 study · 1602 participants
Moderate